{
  "id": "572099930fd6f91b6800000f",
  "type": "yesno",
  "question": "Is acid alpha-glucosidase the enzyme that causes Pompe disease when mutant?",
  "ideal_answer": "Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme responsible for degradation of lysosomal glycogen (acid \u03b1-glucosidase (GAA))",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/18648322",
    "http://www.ncbi.nlm.nih.gov/pubmed/25256446",
    "http://www.ncbi.nlm.nih.gov/pubmed/26029718",
    "http://www.ncbi.nlm.nih.gov/pubmed/14643388",
    "http://www.ncbi.nlm.nih.gov/pubmed/17805474",
    "http://www.ncbi.nlm.nih.gov/pubmed/16702882",
    "http://www.ncbi.nlm.nih.gov/pubmed/8935410",
    "http://www.ncbi.nlm.nih.gov/pubmed/19343043",
    "http://www.ncbi.nlm.nih.gov/pubmed/6442343",
    "http://www.ncbi.nlm.nih.gov/pubmed/20206419",
    "http://www.ncbi.nlm.nih.gov/pubmed/15639117",
    "http://www.ncbi.nlm.nih.gov/pubmed/25217571",
    "http://www.ncbi.nlm.nih.gov/pubmed/8552676",
    "http://www.ncbi.nlm.nih.gov/pubmed/19862843",
    "http://www.ncbi.nlm.nih.gov/pubmed/19371716",
    "http://www.ncbi.nlm.nih.gov/pubmed/15585405",
    "http://www.ncbi.nlm.nih.gov/pubmed/9505277",
    "http://www.ncbi.nlm.nih.gov/pubmed/19775921",
    "http://www.ncbi.nlm.nih.gov/pubmed/11468225",
    "http://www.ncbi.nlm.nih.gov/pubmed/25036864",
    "http://www.ncbi.nlm.nih.gov/pubmed/17095274",
    "http://www.ncbi.nlm.nih.gov/pubmed/9668092",
    "http://www.ncbi.nlm.nih.gov/pubmed/25786784",
    "http://www.ncbi.nlm.nih.gov/pubmed/9883081",
    "http://www.ncbi.nlm.nih.gov/pubmed/11906",
    "http://www.ncbi.nlm.nih.gov/pubmed/12409258"
  ],
  "snippets": [
    {
      "text": "Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme responsible for degradation of lysosomal glycogen (acid \u03b1-glucosidase (GAA))",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029718",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pompe disease is a systemic metabolic disorder characterized by lack of acid-alpha glucosidase (GAA) resulting in ubiquitous lysosomal glycogen accumulation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25217571",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pompe disease is an autosomal recessive myopathic disorder caused by the deficiency of lysosomal acid \u03b1-glucosidase (GAA)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25256446",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Acid \u03b1-glucosidase deficiency, that is, Pompe disease, is a glycogenosis for which enzyme replacement therapy (ERT) is available",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25786784",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The analysis revealed that the amino acid substitutions causing a processing or transport defect responsible for Pompe disease were widely spread over all of the five domains comprising the acid alpha-glucosidase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19343043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pompe disease is a lysosomal storage disease (LSD) caused by a deficiency in the lysosomal enzyme acid alpha-glucosidase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20206419",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glycogen storage disease type II (GSDII; Pompe disease or acid maltase deficiency) is an autosomal recessive disorder caused by lysosomal acid alpha-glucosidase (AalphaGlu) deficiency and manifests predominantly as skeletal muscle weakness.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17095274",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Structural study on a mutant acid alpha-glucosidase in silico combined with biochemical investigation is useful for understanding the molecular pathology of Pompe disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17805474",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The nature of mutant acid alpha-glucosidase (AAG) in muscle was studied in 6 patients with Pompe disease, consisting of 2 each of the infantile, childhood and adult types.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6442343",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pompe disease (glycogen storage disease II) is caused by mutations in the acid alpha-glucosidase gene.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18648322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glycogen storage disease type II (Pompe disease) is inherited by autosomal recessive transmission and caused by a deficiency of acid alpha-glucosidase (GAA), resulting in impaired degradation and lysosomal accumulation of glycogen.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14643388",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pompe disease is a lysosomal storage disorder (LSD) caused by mutations in the gene that encodes acid alpha-glucosidase (GAA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19862843",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Demonstration of acid alpha-glucosidase in different types of Pompe disease by use of an immunochemical method.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6442343",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Acid alpha-glucosidase (GAA) deficiency causes Pompe disease, a lethal lysosomal glycogen storage disease for which no effective treatment currently exists.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9505277",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Deficiency of acid alpha glucosidase (GAA) causes Pompe disease, which is usually fatal if onset occurs in infancy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16702882",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Infantile Pompe disease is caused by deficiency of lysosomal acid alpha-glucosidase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16702882",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11468225",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25036864",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Structural study on a mutant acid alpha-glucosidase in silico combined with biochemical investigation is useful for understanding the molecular pathology of Pompe disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17805474",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12409258",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Although many lysosomal disorders are corrected by a small amount of the missing enzyme, it has been generally accepted that 20-30% of normal acid alpha-glucosidase (GAA) activity, provided by gene or enzyme replacement therapy, would be required to reverse the myopathy and cardiomyopathy in Pompe disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12409258",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The nature of mutant acid alpha-glucosidase (AAG) in muscle was studied in 6 patients with Pompe disease, consisting of 2 each of the infantile, childhood and adult types",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6442343",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As in the severe human infantile disease (Pompe Syndrome), mice homozygous for disruption of the acid alpha-glucosidase gene (6(neo)/6(neo)) lack enzyme activity and begin to accumulate glycogen in cardiac and skeletal muscle lysosomes by 3 weeks of age, with a progressive increase thereafter",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9668092",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glycogen-storage disease type II, Pompe disease, is caused by the deficiency of acid alpha-D-glucosidase in lysosome",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8935410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pompe disease (glycogen storage disease II) is caused by mutations in the acid alpha-glucosidase gene",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18648322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glycogen storage disease type II (Pompe disease) is inherited by autosomal recessive transmission and caused by a deficiency of acid alpha-glucosidase (GAA), resulting in impaired degradation and lysosomal accumulation of glycogen",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14643388",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12409258",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Structural modeling of mutant alpha-glucosidases resulting in a processing/transport defect in Pompe disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19343043",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15585405",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25036864",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pompe disease is an autosomal recessive muscle-wasting disorder caused by the deficiency of the lysosomal enzyme acid alpha-glucosidase. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15639117",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Structural study on a mutant acid alpha-glucosidase in silico combined with biochemical investigation is useful for understanding the molecular pathology of Pompe disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17805474",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We describe an improved method for detecting deficiency of the acid hydrolase, alpha-1,4-glucosidase in leukocytes, the enzyme defect in glycogen storage disease Type II (Pompe disease).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11906",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Acid alpha-glucosidase (GAA) deficiency causes Pompe disease,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9505277",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Infantile Pompe disease is caused by deficiency of lysosomal acid alpha-glucosidase. Trials with recombinant human acid alpha-glucosidase enzyme replacement therapy (ERT) show a decrease in left ventricular mass and improved function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16702882",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Pompe disease is an autosomal recessive muscle-wasting disorder caused by the deficiency of the lysosomal enzyme acid alpha-glucosidase. Due to virtual absence of acid alpha-glucosidase, patients with classical infantile Pompe disease develop progressive cardiomyopathy, skeletal muscle weakness and respiratory insufficiency leading to death in early infancy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15639117",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pompe disease is caused by the congenital deficiency of the lysosomal enzyme acid alpha-glucosidase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9883081",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The nature of mutant acid alpha-glucosidase (AAG) in muscle was studied in 6 patients with Pompe disease,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6442343",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Pompe disease is a lysosomal storage disorder (LSD) caused by mutations in the gene that encodes acid alpha-glucosidase (GAA). Recently, small molecule pharmacological chaperones have been shown to increase protein stability and cellular levels for mutant lysosomal enzymes and have emerged as a new therapeutic strategy for the treatment of LSDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19862843",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Acid alpha-glucosidase (GAA) deficiency causes Pompe disease, a lethal lysosomal glycogen storage disease for which no effective treatment currently exists.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9505277",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Infantile Pompe disease is caused by deficiency of lysosomal acid alpha-glucosidase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16702882",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glycogen-storage disease type II, Pompe disease, is caused by the deficiency of acid alpha-D-glucosidase in lysosome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8935410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Structural modeling of mutant alpha-glucosidases resulting in a processing/transport defect in Pompe disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19343043",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pompe disease is a lysosomal storage disorder (LSD) caused by mutations in the gene that encodes acid alpha-glucosidase (GAA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19862843",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Structural study on a mutant acid alpha-glucosidase in silico combined with biochemical investigation is useful for understanding the molecular pathology of Pompe disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17805474",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16702882",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Mutations in alpha-glucosidase cause accumulation of glycogen in lysosomes, resulting in Pompe disease, a lysosomal storage disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371716",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pompe disease is an autosomal recessive muscle-wasting disorder caused by the deficiency of the lysosomal enzyme acid alpha-glucosidase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15639117",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Infantile Pompe disease is a fatal genetic muscle disorder caused by a deficiency of acid alpha-glucosidase, a glycogen-degrading lysosomal enzyme.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8552676",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}